294 related articles for article (PubMed ID: 30409309)
1. Carcinogenic epithelial-mesenchymal transition initiated by oral cancer exosomes is inhibited by anti-EGFR antibody cetuximab.
Fujiwara T; Eguchi T; Sogawa C; Ono K; Murakami J; Ibaragi S; Asaumi JI; Calderwood SK; Okamoto K; Kozaki KI
Oral Oncol; 2018 Nov; 86():251-257. PubMed ID: 30409309
[TBL] [Abstract][Full Text] [Related]
2. Anti-EGFR antibody cetuximab is secreted by oral squamous cell carcinoma and alters EGF-driven mesenchymal transition.
Fujiwara T; Eguchi T; Sogawa C; Ono K; Murakami J; Ibaragi S; Asaumi JI; Okamoto K; Calderwood SK; Kozaki KI
Biochem Biophys Res Commun; 2018 Sep; 503(3):1267-1272. PubMed ID: 30017201
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor/epidermal growth factor receptor signaling blockage inhibits tumor cell-derived exosome uptake by oral squamous cell carcinoma through macropinocytosis.
Sasabe E; Tomomura A; Liu H; Sento S; Kitamura N; Yamamoto T
Cancer Sci; 2022 Feb; 113(2):609-621. PubMed ID: 34874595
[TBL] [Abstract][Full Text] [Related]
4. Eribulin sensitizes oral squamous cell carcinoma cells to cetuximab via induction of mesenchymal-to-epithelial transition.
Kitahara H; Hirai M; Kato K; Bou-Gharios G; Nakamura H; Kawashiri S
Oncol Rep; 2016 Dec; 36(6):3139-3144. PubMed ID: 27779690
[TBL] [Abstract][Full Text] [Related]
5. EGF induces epithelial-mesenchymal transition and cancer stem-like cell properties in human oral cancer cells via promoting Warburg effect.
Xu Q; Zhang Q; Ishida Y; Hajjar S; Tang X; Shi H; Dang CV; Le AD
Oncotarget; 2017 Feb; 8(6):9557-9571. PubMed ID: 27926487
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of epithelial-mesenchymal transition by cetuximab via the EGFR-GEP100-Arf6-AMAP1 pathway in head and neck cancer.
Matsumoto Y; Sakurai H; Kogashiwa Y; Kimura T; Matsumoto Y; Shionome T; Asano M; Saito K; Kohno N
Head Neck; 2017 Mar; 39(3):476-485. PubMed ID: 27880014
[TBL] [Abstract][Full Text] [Related]
7. Epidermal Growth Factor (EGF) Autocrine Activation of Human Platelets Promotes EGF Receptor-Dependent Oral Squamous Cell Carcinoma Invasion, Migration, and Epithelial Mesenchymal Transition.
Chen R; Jin G; Li W; McIntyre TM
J Immunol; 2018 Oct; 201(7):2154-2164. PubMed ID: 30150285
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin Plus Cetuximab Inhibits Cisplatin-Resistant Human Oral Squamous Cell Carcinoma Cell Migration and Proliferation but Does Not Enhance Apoptosis.
Choi HS; Kim YK; Yun PY
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360933
[TBL] [Abstract][Full Text] [Related]
9. Novel EGFR ectodomain mutations associated with ligand-independent activation and cetuximab resistance in head and neck cancer.
Nair S; Trummell HQ; Rajbhandari R; Thudi NK; Nozell SE; Warram JM; Willey CD; Yang ES; Placzek WJ; Bonner JA; Bredel M
PLoS One; 2020; 15(2):e0229077. PubMed ID: 32069320
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia Mediates Differential Response to Anti-EGFR Therapy in HNSCC Cells.
Wiechec E; Hansson KT; Alexandersson L; Jönsson JI; Roberg K
Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28468237
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibody cetuximab impairs matrix metalloproteinases 2 and 9, epithelial-mesenchymal transition and cell migration in feline oral squamous cell carcinoma in vitro.
Altamura G; Martano M; Matrone A; Corteggio A; Borzacchiello G
Vet Comp Oncol; 2024 Mar; 22(1):149-155. PubMed ID: 38030131
[TBL] [Abstract][Full Text] [Related]
12. EGF/TGFβ1 co-stimulation of oral squamous cell carcinoma cells causes an epithelial-mesenchymal transition cell phenotype expressing laminin 332.
Richter P; Umbreit C; Franz M; Berndt A; Grimm S; Uecker A; Böhmer FD; Kosmehl H; Berndt A
J Oral Pathol Med; 2011 Jan; 40(1):46-54. PubMed ID: 20819124
[TBL] [Abstract][Full Text] [Related]
13. Acquisition cancer stemness, mesenchymal transdifferentiation, and chemoresistance properties by chronic exposure of oral epithelial cells to arecoline.
Wang TY; Peng CY; Lee SS; Chou MY; Yu CC; Chang YC
Oncotarget; 2016 Dec; 7(51):84072-84081. PubMed ID: 27557511
[TBL] [Abstract][Full Text] [Related]
14. A potential link between desmoglein 3 and epidermal growth factor receptor in oral squamous cell carcinoma and its effect on cetuximab treatment efficacy.
Minabe M; Akiyama Y; Higa K; Tachikawa T; Takahashi S; Nomura T; Kouno M
Exp Dermatol; 2019 May; 28(5):614-617. PubMed ID: 30907457
[TBL] [Abstract][Full Text] [Related]
15. Epithelial-mesenchymal-transition induced by EGFR activation interferes with cell migration and response to irradiation and cetuximab in head and neck cancer cells.
Holz C; Niehr F; Boyko M; Hristozova T; Distel L; Budach V; Tinhofer I
Radiother Oncol; 2011 Oct; 101(1):158-64. PubMed ID: 21665310
[TBL] [Abstract][Full Text] [Related]
16. Bovine lactoferrin reverses programming of epithelial-to-mesenchymal transition to mesenchymal-to-epithelial transition in oral squamous cell carcinoma.
Chea C; Miyauchi M; Inubushi T; Okamoto K; Haing S; Nguyen PT; Imanaka H; Takata T
Biochem Biophys Res Commun; 2018 Dec; 507(1-4):142-147. PubMed ID: 30415774
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia activated EGFR signaling induces epithelial to mesenchymal transition (EMT).
Misra A; Pandey C; Sze SK; Thanabalu T
PLoS One; 2012; 7(11):e49766. PubMed ID: 23185433
[TBL] [Abstract][Full Text] [Related]
18. Combination of NTP with cetuximab inhibited invasion/migration of cetuximab-resistant OSCC cells: Involvement of NF-κB signaling.
Chang JW; Kang SU; Shin YS; Seo SJ; Kim YS; Yang SS; Lee JS; Moon E; Lee K; Kim CH
Sci Rep; 2015 Dec; 5():18208. PubMed ID: 26655729
[TBL] [Abstract][Full Text] [Related]
19. Distinct effects of EGFR inhibitors on epithelial- and mesenchymal-like esophageal squamous cell carcinoma cells.
Yoshioka M; Ohashi S; Ida T; Nakai Y; Kikuchi O; Amanuma Y; Matsubara J; Yamada A; Miyamoto S; Natsuizaka M; Nakagawa H; Chiba T; Seno H; Muto M
J Exp Clin Cancer Res; 2017 Aug; 36(1):101. PubMed ID: 28764725
[TBL] [Abstract][Full Text] [Related]
20. Effects of activated fibroblasts on phenotype modulation, EGFR signalling and cell cycle regulation in OSCC cells.
Berndt A; Büttner R; Gühne S; Gleinig A; Richter P; Chen Y; Franz M; Liebmann C
Exp Cell Res; 2014 Apr; 322(2):402-14. PubMed ID: 24394543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
